TuHURA Biosciences, Inc. - Common Stock · Transaction Jul 13, 2025 · Filed Aug 9, 2025 · $50,001 to $100,000
TuHURA Biosciences Inc
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is HURA moving today?
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
HURA overview
Related filings and maps
Congress activity in HURA
TuHURA Biosciences, Inc. - Common Stock · Transaction Nov 25, 2024 · Filed Jan 7, 2025 · $1,001 to $15,000
TuHURA Biosciences, Inc. - Common Stock · Transaction Oct 18, 2024 · Filed Nov 21, 2024 · $100,001 to $250,000
HURA contract awards, year to date.
Public federal awards linked to this ticker.
HURA lobbying filings, year to date.
Registered lobbying filings matched to TuHURA Biosciences Inc.